Hillsdale Investment Management Inc. Has $577,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Hillsdale Investment Management Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 33.4% in the fourth quarter, HoldingsChannel reports. The fund owned 3,992 shares of the company’s stock after selling 2,000 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Johnson & Johnson were worth $577,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of JNJ. Principal Financial Group Inc. increased its position in shares of Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after acquiring an additional 329,473 shares in the last quarter. United Bank increased its holdings in Johnson & Johnson by 5.6% during the 3rd quarter. United Bank now owns 3,788 shares of the company’s stock worth $614,000 after purchasing an additional 202 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Johnson & Johnson in the third quarter worth approximately $365,000. Algert Global LLC purchased a new position in shares of Johnson & Johnson during the third quarter valued at approximately $721,000. Finally, Cahill Financial Advisors Inc. grew its holdings in Johnson & Johnson by 12.8% during the third quarter. Cahill Financial Advisors Inc. now owns 4,038 shares of the company’s stock worth $654,000 after buying an additional 459 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $163.43 on Tuesday. The business’s fifty day moving average is $157.37 and its 200 day moving average is $156.16. The firm has a market cap of $393.83 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the prior year, the business posted $2.29 earnings per share. The company’s revenue was up 5.3% on a year-over-year basis. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Analyst Ratings Changes

JNJ has been the topic of a number of analyst reports. Leerink Partners cut their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Wells Fargo & Company decreased their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 10th. Finally, Raymond James dropped their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.